Intravenous Glutathione

Glutathione as a molecule

Glutathione is described in a 2008 review as the most abundant low molecular weight thiol compound synthesized in cells, with roles in protecting cells from oxidative damage and from the toxicity of foreign electrophilic compounds, and in maintaining redox balance. A 2026 review describes it as a tripeptide made of glutamate, cysteine and glycine. The abbreviation GSH is used for the reduced form and GSSG for the oxidized form.

Early clinical use in oncology

Trials of glutathione given by infusion alongside cisplatin chemotherapy were published in the 1990s. A 1995 double-blind, placebo-controlled trial in 50 people with advanced gastric cancer tested glutathione as protection against cisplatin-induced nerve damage, and the authors described it as a promising agent for that purpose. This is the clinical setting in which injected glutathione has the longest research record in the sources reviewed.

Spread to cosmetic skin lightening

A 2016 review reported that oral and intravenous glutathione had been available for many years in some countries, including the Philippines, and had more recently reached India. A 2026 review links global demand for skin-lightening products to social and cultural factors, including the perceived beauty and social status attached to lighter skin tones, and describes intravenous glutathione as a prominent cosmetic skin-lightening treatment despite continuing uncertainty about its efficacy and safety.

Names and forms

Sources use intravenous glutathione, IV glutathione and glutathione injection for the practice. A 2016 review lists parenteral glutathione as including intravenous and intramuscular forms, and notes that the molecule has also been given by intranasal and intrabronchial routes. A Philippine health advisory refers to intravenous drip or infusion with reduced glutathione, and the term glutathione drip is used for the same practice in clinic settings.

Related agents and confusable terms

N-acetylcysteine is a different substance. A 2026 review of acetaminophen poisoning states that acetaminophen toxicity develops when glutathione stores become depleted, and that N-acetylcysteine replenishes glutathione and is the standard of care. In that emergency treatment the medicine given is N-acetylcysteine, not glutathione itself.

Intravenous glutathione for skin lightening is often given together with intravenous vitamin C. A 2026 review notes that this co-administration makes it hard to judge the independent effect of glutathione. Machipedia covers the wider family of vitamin and nutrient infusions on the IV Therapy page, and related infusion practices on the Myers' Cocktail, High-Dose Intravenous Vitamin C and NAD+ IV Therapy pages.

What an infusion is in general terms

In intravenous administration a glutathione solution is given into a vein by a trained person, either as a slower infusion or as an injection. A 2026 review states that this route bypasses gastrointestinal and liver metabolism, which is why proponents expect higher systemic exposure than from oral forms. A 2016 review states that intravenous delivery is expected to give complete bioavailability but that no studies support this hypothesis. This page gives no doses, rates or protocols.

Settings and who delivers it

In oncology research the trials were run by medical oncology services alongside chemotherapy. For cosmetic and wellness use, sources describe cosmetic clinics, health and beauty salons, wellness spas and intravenous hydration clinics offering glutathione with vitamin C and other injections. A 2025 case report notes the growth of relatively unregulated intravenous hydration clinics in the United States. Philippine health advisory text warns that risks are of particular concern when a non-medical practitioner gives the treatment or it is done in a non-sterile facility.

Other routes studied

Not all glutathione research concerns infusion. The Parkinson's disease trials of Mischley and colleagues used an intranasal spray, and one imaging study in 15 participants reported higher brain glutathione levels after intranasal use. These results relate to a different route and should not be read as findings about intravenous use.

Skin lightening

The most visible claimed use of intravenous glutathione is cosmetic skin lightening. Reviews describe the proposed mechanism as inhibition of the enzyme tyrosinase, scavenging of reactive oxygen species, and a shift of melanin production from eumelanin toward pheomelanin. A 2026 review states that translating these laboratory mechanisms into clinically meaningful results remains uncertain.

Established and investigational medical uses

A Philippine advisory states that injectable glutathione is approved in that country as an adjunct treatment in cisplatin chemotherapy. Researchers have also tested glutathione for chemotherapy-related nerve damage and, in small trials, for Parkinson's disease. The sources reviewed for this page do not show an established use of intravenous glutathione outside the chemotherapy setting.

General wellness and antioxidant claims

Clinics may describe infusions as antioxidant or wellness support, drawing on the physiological role of glutathione. The sources reviewed describe that role but do not report controlled trials of intravenous glutathione for general wellness in healthy people, and this page makes no detoxification or benefit claim.

Cisplatin neuropathy

A 2014 Cochrane review of agents proposed to prevent nerve damage from cisplatin and related drugs included seven eligible glutathione trials with 387 participants. On a pooled secondary measure, a toxicity grading scale, glutathione was associated with a lower risk of neurotoxicity (relative risk 0.29, 95% confidence interval 0.10 to 0.85). The review concluded that data were insufficient to say that any of the agents, including glutathione, prevent or limit neurotoxicity as measured by objective tests, citing small trials and differing results.

The 1995 trial in 50 people with advanced gastric cancer reported that, after 15 weeks, 4 of 24 assessable participants in the glutathione group had neurotoxicity compared with 16 of 18 in the placebo group, and that nerve conduction findings pointed the same way.

Parkinson's disease

A 2009 randomized, double-blind pilot trial of intravenous glutathione enrolled 21 people with Parkinson's disease over 4 weeks of treatment. Glutathione was well tolerated and adverse events were similar between groups, but there were no significant differences in rating-scale changes. The authors wrote that the data suggested the possibility of a mild symptomatic effect to be tested in a larger study.

Later trials used intranasal glutathione. A 2015 phase I/IIa trial of 30 people found no substantial differences in adverse events between groups. A 2017 phase IIb trial of 45 people found that all groups improved, including placebo, and that neither glutathione group was superior to placebo; one participant in the high-dose group developed cardiomyopathy.

Skin lightening

A 2026 critical review describes the intravenous evidence as very limited, mainly one pilot study and one small randomized trial, with small samples, short follow-up and non-standard outcomes. In the randomized trial, which combined glutathione with vitamin C and enrolled 50 people of whom 32 completed it, 37.5 percent of treated participants were reported to improve, and the review also reports liver enzyme abnormalities in eight participants and one case of anaphylaxis. A 2024 systematic review identified one placebo-controlled intravenous study, with a difference that did not reach conventional significance (p 0.054), and its authors concluded that intravenous use is contraindicated because of lack of efficacy and side effects.

Most controlled data concern other routes. A 2019 systematic review of four studies of oral or topical glutathione called the evidence inconclusive because of study quality and inconsistent findings. A 2017 oral trial in healthy women over 12 weeks reported tendencies toward lower melanin index than placebo. These results should not be carried over to intravenous use.

Searches and gaps

PubMed searches on skin lightening, Parkinson's disease, cisplatin neurotoxicity and Stevens-Johnson syndrome found no controlled trial of intravenous glutathione for general wellness, and no source covered inhaled glutathione for cystic fibrosis.

Harms reported in cosmetic use

A 2026 review lists infusion-related reactions such as nausea, flushing, dizziness and malaise, hypersensitivity reactions including anaphylaxis, raised liver enzymes, and sporadic reports of thyroid and kidney changes. It rates causality for the liver, thyroid and kidney findings as uncertain and describes the long-term safety of intravenous use as unknown because follow-up in studies was only weeks. A 2019 Philippine advisory states that side effects of injectable glutathione for skin lightening include toxic effects on the liver, kidneys and nervous system, and a possibility of Stevens-Johnson syndrome.

The same advisory raises theoretical concerns about long-term skin cancer risk, and warns of transmission of infectious agents such as HIV and hepatitis B and C when injections are given by non-medical practitioners or in non-sterile facilities. It adds that vitamin C injections, often paired with glutathione, may form kidney stones in acidic urine and have led to hemodialysis in people with G6PD deficiency after large doses.

Case reports and product quality

A 2025 case report described a 33-year-old woman who developed Stevens-Johnson syndrome or toxic epidermal necrolysis, severe skin reactions with high morbidity and mortality, after an intravenous vitamin infusion containing glutathione, vitamin C and vitamin D. Because several ingredients were given together, the report cannot attribute the reaction to glutathione alone.

A 2016 review says proponents suggest adverse effects may come from additives in injection vials, and that cheaper products may be counterfeit with a risk of life-threatening events. The sources opened for this page did not report specific contaminants such as heavy metals in glutathione products.

Statements from health bodies and professionals

The Philippine Food and Drug Administration advisory states that no published clinical trials had evaluated injectable glutathione for skin lightening, that it had not approved any injectable product for that purpose, and that people should consult only a board-certified dermatologist and avoid buying injectable products online. A 2016 dermatology review advised dermatologists to refrain from giving such injections for skin lightening until better studies show a favorable benefit-to-risk balance. A statement from the Philippine Dermatological Society was not available on an open page and is not cited here.

Intravenous glutathione is not a substitute for care of chemotherapy side effects, Parkinson's disease or acetaminophen poisoning, which are managed by clinicians. Anyone with a severe rash, swelling, breathing difficulty or jaundice after an infusion needs urgent medical attention, as the cited case report and advisory describe reactions of that kind.